ARTICLE | Company News
Amrad, Ludwig Institute for Cancer Research, Rhone-Poulenc Rorer deal
February 8, 1999 8:00 AM UTC
AML and the institute granted RPR's RPR Gencell gene therapy division exclusive rights to vascular endothelial growth factor B (VEGF-B) in cardiovascular disease. AML and the institute will share $50...